In addition, four other PD-1 antibodies (Sintilima, Toripalimab, Penpilimab, and Zzimberelimab) have been approved in China for the therapy of resectable or metastatic melanoma, nasopharyngeal carcinoma, urothelial carcinoma, as well as relapsed or refractory classical Hodgkin lymphoma [346]. This evidence concerns the gene PDCD1 and metastatic melanoma.